J
Joshua J. Souchek
Researcher at University of Nebraska Medical Center
Publications - 21
Citations - 1022
Joshua J. Souchek is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Pancreatic cancer & Cancer. The author has an hindex of 17, co-authored 20 publications receiving 770 citations. Previous affiliations of Joshua J. Souchek include Eppley Institute for Research in Cancer and Allied Diseases & Creighton University.
Papers
More filters
Journal ArticleDOI
Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: Applications in diagnosis and therapy
María P. Torres,Satyanarayana Rachagani,Joshua J. Souchek,Kavita Mallya,Sonny L. Johansson,Surinder K. Batra,Surinder K. Batra +6 more
TL;DR: The successful establishment and characterization of three cell lines derived from two PDAC mouse models that mimic the genetic compendium of human PDAC make them valuable models with a high potential of translational relevance for examining diagnostic markers and therapeutic drugs.
Journal ArticleDOI
Ossifying Fibromyxoid Tumor of Soft Parts: A Clinicopathologic, Proteomic and Genomic Study
Rondell P. Graham,Sarah M. Dry,Xin-Min Li,Scott W. Binder,Armita Bahrami,Susana C. Raimondi,Ahmet Dogan,Subhankar Chakraborty,Joshua J. Souchek,Andrew L. Folpe +9 more
TL;DR: It is concluded that malignant of soft tissue and bone tumor of borderline malignancy exist and may be recognized by the previously proposed criteria of Folpe and Weiss.
Journal ArticleDOI
Impact of structurally modifying hyaluronic acid on CD44 interaction
Deep S. Bhattacharya,Denis Svechkarev,Joshua J. Souchek,Tanner K. Hill,Margaret A. Taylor,Amarnath Natarajan,Amarnath Natarajan,Aaron M. Mohs +7 more
TL;DR: These studies indicated that while both deacetylation and sulfation of HA individually decrease CD44 interaction, both chemical modifications are required to minimize interaction with CD44+ cells.
Journal ArticleDOI
Mucin-based targeted pancreatic cancer therapy
TL;DR: An overview of the therapies targeting mucins in PC, including immunotherapy (i.e. vaccines, antibodies, and radioimmunoconjugates), gene therapy, and other novel therapeutic strategies are presented.
Journal ArticleDOI
Biological determinants of radioresistance and their remediation in pancreatic cancer
Parthasarathy Seshacharyulu,Michael J. Baine,Joshua J. Souchek,Melanie Menning,Sukhwinder Kaur,Ying Yan,Michel M. Ouellette,Maneesh Jain,Chi Lin,Surinder K. Batra +9 more
TL;DR: Molecular mechanisms associated with the radio-resistant phenotype of pancreatic cancer are summarized and the need for examining selective radioprotectors in light of the emerging evidence on radiation toxicity to non-target tissue associated with PC radiotherapy is discussed.